New hope for cancer patients: drug combo aims to stop Chemo-Induced nausea
NCT ID NCT07413809
First seen Feb 19, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This study tests whether a new combination of anti-nausea drugs (fosaprepitant, tropisetron, and olanzapine) works better than the standard combo (fosaprepitant, tropisetron, and dexamethasone) for preventing delayed nausea and vomiting after high-dose chemotherapy in multiple myeloma patients receiving their own stem cells. About 92 adults will take part. The goal is to see if the new regimen helps more patients avoid vomiting without needing extra medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated People's Hospital of Ningbo University
RECRUITINGNingbo, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.